Clinical Trial Update: Effect of Pioglitazone on Inflammation in Cystic Fibrosis [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial assessing pioglitazone for reducing inflammation in cystic fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Actos (pioglitazone) (pioglitazone)

Snippet

Sponsor: Paul Beringer | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED